CFDE Data Portal | Search LINC02608

	Label	Description
	LINC02608 Gene (Entity type)	ENSG00000226251 - long intergenic non-protein coding RNA 2608
	GSE126463 pomalidomide MM1.S 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE173201 cisplatin 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE163240 enzalutamide 2 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE192710 ZIC2 ZNF423 inhibition stem cell 4 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 dexamethasone 2 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 XPO1 inhibition Dexamethasone 2 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GTEx AdrenalGland 20-29 vs 50-59 Down Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Spleen 20-29 vs 60-69 Up Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Liver 20-29 vs 70-79 Up Gene Set (Entity type)	A Gene Set from GTEx

LINC02608

ENSG00000226251 - long intergenic non-protein coding RNA 2608

GSE126463 pomalidomide MM1.S 4 v 2 human up

A Gene Set from LINCS

GSE173201 cisplatin 2 v 1 human up

A Gene Set from LINCS

GSE163240 enzalutamide 2 v 4 human dn

A Gene Set from LINCS

GSE192710 ZIC2 ZNF423 inhibition stem cell 4 v 5 human up

A Gene Set from LINCS

GSE135350 dexamethasone 2 v 6 human up

A Gene Set from LINCS

GSE135350 XPO1 inhibition Dexamethasone 2 v 6 human up

A Gene Set from LINCS

GTEx AdrenalGland 20-29 vs 50-59 Down

A Gene Set from GTEx

GTEx Spleen 20-29 vs 60-69 Up

A Gene Set from GTEx

GTEx Liver 20-29 vs 70-79 Up

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.